Company Overview
Galmed Pharmaceuticals Ltd. operates as a biopharmaceutical entity dedicated to the development of therapeutics specifically designed for the treatment of liver diseases. Within the broader Healthcare sector and the Biotechnology industry, this focus implies a strategic orientation toward specialized drug discovery and clinical advancement rather than broad consumer pharmaceutical products. The company maintains a market capitalization of $3.32M and employs a workforce of 3 individuals, indicating a highly lean operational structure typical of early-stage research entities. The combination of a market cap in the low millions and reported annual revenue figures that are unavailable suggests the company is currently in a phase where capital allocation is driven by research and development expenditures rather than commercial sales generation.
Financial Health
The company reports a Net Income (TTM) of $-8,700,000 and an EBITDA of $-7,049,750, while Revenue (TTM) is listed as N/A, a situation common for companies in the clinical development stage where costs significantly outpace current sales. The absence of reported revenue alongside substantial net losses reveals a cost structure dominated by research and development expenses and clinical trial costs rather than operational overhead or cost of goods sold associated with commercialization. Free Cash Flow stands at $-4,574,250, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for distribution. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting that the company has not yet achieved commercial profitability or that revenue data is insufficient to calculate these ratios. Total cash on hand is $19.05M, whereas Debt is N/A, meaning the balance sheet does not carry traditional interest-bearing liabilities and relies solely on equity financing. With a Current Ratio of 7.98, the company possesses substantial short-term liquid assets relative to its current liabilities, suggesting a robust ability to meet immediate financial obligations without distress. Return on Equity is -46.3% and Return on Assets is -20.9%, metrics that indicate management is currently burning through equity and asset base value to advance the Aramchol therapeutic into Phase III studies rather than generating returns for shareholders.
Valuation Assessment
The Trailing P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is listed as -0.49, implying that analysts or data providers project continued negative earnings in the near term rather than a path to immediate profitability. The Price to Book ratio is 0.14, indicating that the market values the company at a fraction of its net asset value, which often signals high perceived risk or a lack of tangible assets relative to market expectations. The Price to Sales ratio is N/A, and the EV/EBITDA stands at 2.31, suggesting that valuation is being assessed primarily on enterprise value relative to earnings before interest, taxes, depreciation, and amortization despite those earnings being negative. The 52-Week High is $2.68 and the 52-Week Low is $0.41, creating a trading range where the current price position depends on the specific share price which is not explicitly provided in the facts but is bounded by these extremes. The Beta value is 0.42, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting less sensitivity to general market fluctuations compared to large-cap equities.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, precluding any analysis of whether earnings are growing faster or slower than revenue in a historical context. Since the company is not a dividend payer, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning all available earnings are theoretically available for reinvestment, though currently consumed by operational losses. This profile indicates that the company reinvests its entire financial focus into growth initiatives such as advancing the Aramchol molecule through clinical trials rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by a complete absence of current income generation, relying entirely on the successful commercialization of future products to realize growth potential.